logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 3 of 3 Items
Showing 1 - 3 of 3 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Review

Paving the way for affordable and equitable liposomal amphotericin B access worldwide

Lee JSF, Cohen RM, Khan RA, Burry J, Casas EC,  et al.
2024-09-01 • Lancet Global Health
2024-09-01 • Lancet Global Health
Journal Article
|
Research

A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh

Sundar S, Pandey K, Mondal D, Madhukar M, Kamal Topno R,  et al.
2024-06-20 • PLOS Neglected Tropical Diseases
2024-06-20 • PLOS Neglected Tropical Diseases
BACKGROUND
In Southeast Asia, treatment is recommended for all patients with post-kala-azar dermal leishmaniasis (PKDL). Adherence to the first-line regimen, twelve weeks of miltefos...
Conference Material
|
Abstract

Safety and efficacy data from a phase 2 randomized trial of a miltefosine/thermotherapy combination in uncomplicated New World cutaneous leishmaniasis

Arana B, Lopez L, Velez ID, Llanos-Cuentas A, Boni MF,  et al.
2020-05-13 • MSF Scientific Days International 2020: Research
2020-05-13 • MSF Scientific Days International 2020: Research